Last updated: May 24, 2026
Tolmetin sodium is a legacy nonsteroidal anti-inflammatory drug (NSAID). Supplier selection is driven by (1) whether you need tolmetin sodium API versus finished dosage forms (tablets), (2) regulatory standing in target markets (FDA/Orange Book for US, EMA/MHRA listings for EU/UK), and (3) contractual controls on polymorph/hydrate state, particle size, and DMF-level impurity specs for USDMF-referenced API.
Because supplier shortlists must be tied to identifiable, current regulatory listings (FDA drug master files, Orange Book NDA references, inspections, and country-of-origin traceability), a complete and accurate supplier map cannot be produced from the information provided.
Which companies supply tolmetin sodium API vs finished tablets?
Featured snippet answer: Tolmetin sodium is supplied either as API (to generic and private label manufacturers) or as the finished tablet dosage form by legacy generic firms; the correct “supplier” list depends on whether you are sourcing API or tablets and which geography you target.
API supply: common sourcing routes
- DMF-backed API manufacturers that sell tolmetin sodium API to multiple formulators.
- Contract API manufacturers supplying to generic tablet packagers.
- Re-packagers that do not manufacture the API (to be treated as distributors, not API sources).
Finished dosage supply
- Generic tablet manufacturers that hold finished drug registrations and build product using sourced API.
- License-and-manufacture arrangements where the tablet maker differs from the API manufacturer.
What regulatory listings determine whether a tolmetin sodium supplier is “real” for US?
Featured snippet answer: In the US, “real” suppliers for sourcing decisions are identified through FDA records tied to (a) DMFs (API) and (b) approved ANDAs/OTC/ANDA references and product labeling (finished tablets). Orange Book confirms approved products at the NDA/ANDA level; DMF confirms API access pathways.
How US sourcing is typically vetted
- Confirm FDA approval status of each finished dosage via Orange Book listings for “tolmetin sodium” tablet products.
- Trace each product to the NDA/ANDA holder and, where possible, to the manufacturing site(s) on labeling/annual reports.
- For API, use the DMF reference chain to identify the API holder(s) and the specific named manufacturer(s) on the DMF.
Which intermediates and specs matter for tolmetin sodium sourcing?
Tolmetin sodium supplier risk is largely controlled by chemistry and quality attributes that affect impurity profile and downstream tablet performance.
Critical quality attributes to require in supplier qualification
- Water content and salt form control for tolmetin sodium (sodium salt stability and handling).
- Impurity profile aligned to regulatory specifications for the approved generic product you will manufacture.
- Particle size distribution and flow properties for tablet blending consistency.
- Residual solvents and process impurities consistent with the supplier’s validated route.
Testing package to lock before contracting
- Full impurity panel with acceptance limits aligned to your intended registration.
- Solid-state characterization for batch consistency (salt confirmation).
- Stability program commitments for API (accelerated and long-term) at your intended storage conditions.
What due diligence blocks supply chain disruptions for tolmetin sodium?
Featured snippet answer: Shortlists fail when suppliers cannot support consistent lot release, stable impurity specs, or inspection readiness. Treat API and tablet manufacturing as inspection-risk items, not as price-only decisions.
Due diligence checklist for contracting
- Recent FDA inspection history for the API or finished drug manufacturing site(s).
- Batch-to-batch consistency evidence (COAs across multiple lots).
- Change control history (process, site, and specification changes) and notification SLAs.
- Ability to support regulatory submissions (DMF, amendments, letter of authorization if needed).
- Packaging integrity, cold chain needs (if any), and warehousing control.
How do you compare tolmetin sodium suppliers by capability?
Featured snippet answer: Compare suppliers on regulatory track record, DMF-backed API access (if API sourcing), quality system maturity, and ability to meet tablet performance specs.
Comparison framework (usable for RFP scorecards)
- Regulatory linkage: DMF availability and OR Orange Book product linkage via finished drug maker.
- Manufacturing capacity: number of lots per quarter, lead time, and minimum order quantities.
- Quality systems: deviation frequency trend, CAPA turnaround, and audit outcomes.
- Technical fit: supported particle size/grade, impurity specs, and supported tablet excipient compatibility.
- Geographic supply reliability: export documentation readiness and customs throughput.
What generic entry risks exist if you rely on a single tolmetin sodium supplier?
Tolmetin sodium is a mature product. The main risk for buyers is not patent exclusivity. It is operational continuity.
Single-source risks
- Lot release failures due to impurity excursions.
- DMF access delays if your planned regulatory path needs direct referencing.
- Unexpected site changes that require regulatory notifications or bridging studies.
Mitigations
- Qualify at least one alternate API source and one alternate finished dosage route.
- Contract for guaranteed supply windows and inspection-ready documentation.
- Require multi-year stability and spec lock language with change notification terms.
Key Takeaways
- “Suppliers for tolmetin sodium” must be segmented into API suppliers versus finished tablet manufacturers; the correct list changes with geography and regulatory pathway.
- US sourcing hinges on FDA-linked records: Orange Book for finished approvals and DMF references for API access.
- Supplier qualification should prioritize impurity control, salt form/water control, particle size/flow for tablet performance, and inspection readiness.
- The dominant commercial risk is supply continuity and lot release reliability, not patent-based exclusivity.
FAQs
-
How do I identify tolmetin sodium API suppliers in the US?
Use FDA DMF-linked records and verify the named manufacturing site(s) that hold the API supply capability.
-
Which tolmetin sodium suppliers are acceptable for generic tablet development?
Only suppliers with regulatory-compatible impurity specs and documented quality systems that can support your intended ANDA/filing strategy.
-
What quality specifications matter most for tolmetin sodium API?
Impurity profile limits, residual solvents/process impurities, salt form/water content control, and particle size distribution.
-
Can distributors be used as tolmetin sodium suppliers for regulatory filings?
Typically only if they provide full traceability to the API holder and supporting regulatory documentation; otherwise treat them as non-qualified resellers.
-
What is the fastest way to reduce supply chain risk for tolmetin sodium?
Qualify a second API source and lock change-control terms and inspection documentation access in the master supply agreement.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
- FDA Drug Master Files (DMF) database and DMF submission records. US Food and Drug Administration.
